There is an increasing amount of evidence suggesting that T cell deficiency contributes to tumor development. However, it is unclear whether T cell deficiency leads to liver and colon carcinogenesis. The aim of this study was to investigate the role of T cells on liver and colon carcinogenesis. Athymic F344/N Jcl-rnu/- (nu/nu) rats and euthymic F344/N Jcl-rnu/+ (nu/+) rats were administered the carcinogen azoxymethane (AOM) at a dose of 15 mg/kg body wt once a week for 2 weeks. At 48 weeks after the second carcinogen treatment, the rats were sacrificed, and livers and colons were examined. Apoptosis and cell proliferation were evaluated by DNA fragmentation and proliferating cell nuclear antigen assays, respectively. Wild-type p53 and members of the Jun and Fos oncogene families were detected by Western blotting. AOM treatment induced 100% liver tumor and 63.6% colon tumor incidence in T cell–deficient nu/nu rats, compared with 0% and 38.5% incidence in nu/+ rats. T cell deficiency promoted the inhibitory action of AOM on apoptosis in both liver and colon at 48 weeks. In contrast, T cell deficiency increased cell proliferation after AOM treatment in both tissues. Wild-type p53 was reduced in both tissues of T cell–deficient rats. AOM treatment induced c-Jun and c-Fos expressions in the liver but increased only Fos B in the colon, whereas T cell deficiency enhanced c-Jun overexpression in the liver. These results suggest that T cell deficiency leads to liver carcinogenesis partly by a reduction in wild-type p53 and increasing c-Jun expression in AOM-treated rats.
ChambersCA, KuhnsMS, EgenJG, AllisonJP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol19: 565–594, 2001.
7.
TerabeM, MatsuiS, Noben-TrauthN, ChenH, WatsonC, DonaldsonDD, CarboneDP, PaulWE, BerzofskyJA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol1: 515–520, 2000.
8.
SarmaS, GuoY, GuillouxY, LeeC, BaiXF, LiuY. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen PIA: normal development but restrained effector function in vivo. J Exp Med189: 811–820, 1999.
9.
WickM, DubeyP, KoeppenH, SiegelCT, FieldsPE, ChenL, BluestoneJA, SchreiberH. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med186: 229–238, 1997.
10.
HansonHL, DonermeyerDL, IkedaH, WhiteJM, ShankaranV, OldLJ, ShikuH, SchreiberRD, AllenPM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity13: 265–276, 2000.
11.
HungK, HayashiR, Lafond-WalkerA, LowensteinC, PardollD, LevitskyH. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med188: 2357–2368, 1998.
12.
PardollDM, TopalianSL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol10: 588–594, 1998.
13.
ToesRE, OssendorpF, OffringaR, MeliefCJ. CD4 T cells and their role in antitumor immune responses. J Exp Med189: 753–756, 1999.
14.
DudleyME, WunderlichJR, RobbinsPF, YangJC, HwuP, SchwartzentruberDJ, TopalianSL, SherryR, RestifoNP, HubickiAM, RobinsonMR, RaffeldM, DurayP, SeippCA, Rogers-FreezerL, MortonKE, MavroukakisSA, WhiteDE, RosenbergSA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science298: 850–854, 2002.
15.
RosenbergSA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med250: 462–475, 2001.
16.
LeeKH, WangE, NielsenMB, WunderlichJ, MiguelesS, ConnorsM, SteinbergSM, RosenbergSA, MarincolaFM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol163: 6292–6300, 1999.
17.
OdaK, ArakawaH, TanakaT, MatsudaK, TanikawaC, MoriT, NishimoriH, TamaiK, TokinoT, NakamuraY, TayaY. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell102: 849–862, 2000.
18.
Jackson-GrusbyL, BeardC, PossematoR, TudorM, FambroughD, CsankovszkiG, DausmanJ, LeeP, WilsonC, LanderE, JaenischR. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet27: 31–39, 2001.
19.
TanakaH, ArakawaH, YamaguchiT, ShiraishiK, FukudaS, MatsuiK, TakeiY, NakamuraY. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature404: 42–49, 2000.
20.
BernalJA, LunaR, EspinaA, LazaroI, Ramos-MoralesF, RomeroF, AriasC, SilvaA, TortoleroM, Pintor-ToroJA. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet32: 306–311, 2002.
21.
DingHF, LinYL, McGillG, JuoP, ZhuH, BlenisJ, YuanJ, FisherDE. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem275: 38905–38911, 2002.
ZwavelingS, VierboomMP, Ferreira MotaSC, HendriksJA, OomsME, SutmullerRP, FrankenKL, NijmanHW, OssendorpF, Van Der BurgSH, OffringaR, MeliefCJ. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res62: 6187–6193, 2002.
24.
ChikamatsuK, AlbersA, StansonJ, KwokWW, AppellaE, WhitesideTL, DeLeoAB. p53110–124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res63: 3675–3681, 2003.
25.
JochumW, PassegueE, WagnerEF. AP-1 in mouse development and tumorigenesis. Oncogene20: 2401–2412, 2001.
26.
VogtPK. Jun, the oncoprotein. Oncogene20: 2365–2377, 2001.
27.
PapanikolaouA, ShankRC, DelkerDA, PoveyA, CooperDP, RosenbergDW. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol Appl Pharmacol150: 196–203, 1998.
WuB, IwakiriR, OotaniA, FujiseT, TsunadaS, FujimotoK. Platelet-activating factor promotes mucosal apoptosis via FasL-mediating caspase-9 active pathway in rat small intestine after ischemia-reperfusion. FASEB J17: 1156–1158, 2003.
30.
WuB, OotaniA, IwakiriR, FujiseT, TsunadaS, TodaS, FujimotoK. Ischemic preconditioning attenuates ischemia/reperfusion-induced mucosal apoptosis by inhibiting the mitochondria-dependent pathway in rat small intestine. Am J Physiol286: G580–G587, 2004.
31.
WuB, FujiseT, IwakiriR, OotaniA, AmemoriS, TsunadaS, TodaS, FujimotoK. Venous congestion induces mucosal apoptosis via tumor necrosis factor-alpha-mediated cell death in the rat small intestine. J Gastroenterol39: 1056–1062, 2004.
32.
WuB, IwakiriR, OotaniA, TsunadaS, FujiseT, SakataY, SakataH, TodaS, FujimotoK. Long-term dietary corn oil ingestion promotes colon cancer invasion by inhibiting mitochondria-dependent apoptosis in azoxymethane-treated rats. Exp Biol Med229: 1017–1025, 2004.
33.
GallagherSR. One-dimensional electrophoresis using nondenaturing conditions. In: AusubelFM, BrentR, KingstonRE, MooreDD, SeidmanJG, SmithJA, StruhlK, Eds. Current Protocols in Molecular Biology. New York:John Wiley & Sons Inc., part 10.2B.1, pp 1–11, 1999.
34.
HerrAE, ThrockmortonDJ, DavenportAA, SinghAK. On-chip native gel electrophoresis-based immunoassays for tetanus antibody and toxin. Anal Chem77: 585–590, 2005.
35.
SeoN, HayakawaS, TokuraY. Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol12: 291–300, 2002.
36.
BoehmU, KlampT, GrootM, HowardJC. Cellular responses to interferon-gamma. Annu Rev Immunol15: 749–795, 1997.
37.
SeoH, TokuraY, FurukawaF, TakigawaM. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type γδ T and αβ T cells co-infiltrating in early B16 melanoma lesions. J Immunol161: 4138–4145, 1998.
38.
SeoN, TokuraY, TakigawaM, EgawaK. Depletion of JJL-10-and TGF-β-producing regulatory γδ T cells by administering a dounomycin-conjugated specific mAb in early tumor lesions augments the activity of CTLs and NK cells. J Immunol163: 242–249, 1999.
39.
FongL, EnglemanEG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol18: 245–273, 2000.
40.
GiacciaAJ, KastanMB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev12: 2973–2983, 1998.
41.
PrivesC. Signaling to p53: breaking the MDM2-p53 circuit. Cell95: 5–8, 1998.
42.
HiraoA, KongYY, MatsuokaS, WakehamA, RulandJ, YoshidaH, LiuD, ElledgeSJ, MakTW. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science287: 1824–1827, 2000.
43.
SharplessNE, DePinhoRA. p53: good cop/bad cop. Cell110: 9–12, 2002.
44.
el-DeiryWS, KernSE, PietenpolJA, KinzlerKW, VogelsteinB. Definition of a consensus binding site for p53. Nat Genet1: 45–49, 1992.
45.
NikolaevAY, LiM, PuskasN, QinJ, GuW. Parc: a cytoplasmic anchor for p53. Cell112: 29–40, 2003.
46.
HuY, Le LeuRK, YoungGP. Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Int J Cancer115: 561–567, 2005.
47.
OlivierM, EelesR, HollsteinM, KhanMA, HarrisCC, HainautP. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutât19: 607–614, 2002.
48.
VousdenKH, PrivesC. P53 and prognosis: new insights and further complexity. Cell120: 7–10, 2005.
49.
ShivapurkarN, BelinskySA, WolfDC, TangZ, AlabasterO. Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Cancer Lett96: 63–70, 1995.
50.
ErdmanSH, WuHD, HixsonLJ, AhnenDJ, GernerEW. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. Mol Carcinog19: 137–144, 1997.
51.
NambiarPR, GiardinaC, GudaK, AizuW, RajaR, RosenbergDW. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res62: 3667–3674, 2002.
52.
CicinnatiVR, DworackiG, AlbersA, BeckebaumS, TutingT, KaczmarekE, DeLeoAB. Impact of p53-based immunization on primary chemically-induced tumors. Int J Cancer113: 961–970, 2005.
53.
KuballJ, SchmitzFW, VossRH, FerreiraEA, EngelR, GuillaumeP, StrandS, RomeroP, HuberC, ShermanLA, TheobaldM. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity22: 117–129, 2005.
54.
JohnsonR, SpiegelmanB, HanahanD, WisdomR. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol16: 4504–4511, 1996.
55.
SchreiberM, KolbusA, PiuF, SzabowskiA, Mohle-SteinleinU, TianJ, KarinM, AngelP, WagnerEF. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev13: 607–619, 1999.
56.
WangZY, SatoH, KusamS, SehraS, ToneyLM, DentAL. Regulation of IL-10 gene expression in th2 cells by jun proteins. J Immunol174: 2098–2105, 2005.
57.
OrdwayJM, WilliamsK, CurranT. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmtl. Oncogene23: 3737–3748, 2004.
58.
HolmesDI, ZacharyI. Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett557: 93–98, 2004.
